Moderna doses first patients across four new Phase I clinical studies
Category: #health  By Paroma Bhattacharya  Date: 2019-08-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna doses first patients across four new Phase I clinical studies

Moderna, a biotech company that focuses on discovery and development of drugs and is based in Cambridge, Massachusetts, announced recently that it has initiated four new Phase I clinical trials, two of which are related to infectious diseases and two in immuno-oncology.

Additionally, in a Phase II study regarding a vaccine for melanoma, first patient has given consent for continuing with the trial. This announcement was made along with the second quarter of 2019 earnings of the company.

Apparently, Moderna’s share rose up by 14% on Nasdaq after the news was announced. The company raised over $600 million after it made its debut in stock market in November 2018, and  the largest initial public offering that was ever made by a biotech company.

According to reports, the company had dosed its first patient in the mRNA-1172’s Phase I study, which is a vaccine made for respiratory syncytial virus (RSV) as well as in mRNA-1893 trial, another vaccine made for Zika virus. For immune-oncology, the company reportedly dozed first patients in the trial for KRAS vaccine for cancer mRNA-5671’S and also a therapy for mRNA-encoding IL12.

Moderna has been developing the KRAS cancer vaccine and the RSV vaccine in partnership with Merck & Co., whereas under the partnership with MedImmune, subsidiary of AstraZeneca, a British drug maker, the company was developing IL12, under the name MEDI1191.

Patients suffering from number of solid tumors together are being co-administered with MEDI1191 with PD-L1 checkpoint inhibitor, AstraZeneca Imfinzi. Drug makers have been taking keen interest in the in the areas of developing KRAS protein for its wide expression in multiple solid tumors, and is considered undruggable owing to its structure.

Reportedly, Amgen has been in the process of developing AMG 510, that targets KRAS G12C, a form of KRAS that has shown efficacy in various patients. Various startups have been involved in the investigation of product candidates that also target KRAS mutations.

 

Source Credit- https://medcitynews.com/2019/08/moderna-builds-up-clinical-pipeline-as-multiple-new-drugs-enter-phase-i-testing/?rf=1



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.